Skip to content
★ Sign in to follow
JS

Jarrett S. Gorlin

CEO
H-Cyte, Inc.
Total declarations
9
Company
1
▲ Purchases (9 ops.)
€197k
▼ Sales (0 ops.)
—

Latest filing published 20 Jun 2017 for H-CYTE, INC., €16k.

Filing timeline

BuySale
Jarrett S. Gorlin

Insider track record

Disclosed buys
9
Disclosed sells
0
Signal history

Closed purchases

Market purchases
9
Positive at T+90
100%
Median T+90
+20.8%

Based on 5 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.

Purchases by company

Since each purchase

  • Filed 07 Jun 2017 · 3442 days ago · €3,948
    -52.7%
    Entry US$952.00 · Close at T+365 US$450.00

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Jarrett S. Gorlin: trading record in brief

This profile gathers the share dealings of Jarrett S. Gorlin in H-Cyte, Inc. The record holds 9 filings, for trades running from 19 April 2016 to 19 June 2017.

The open-market record is one-sided, with 9 purchases worth €197k and not one sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. So far in 2017, the count stands at 7 purchases and no sales.

Half of the purchases are above €4,170 and half below. The 5 purchases reviewed show no overlap with other insiders buying the same stock within a month. After 5 purchases with a full 90-day history, the hit rate stands at 100% and the median 90-day move at +20.8%. Past outcomes like these are no guarantee of what comes next.

The latest filing, published on 20 June 2017, reports an open-market purchase of €16k in H-Cyte, Inc. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. US insiders must file a Form 4 within two business days of a trade. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.

Companies and markets linked to Jarrett S. Gorlin

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations9 total
  • ▲
    CHIEF EXECUTIVE OFFICERExecutivesH-Cyte, Inc.
    18,000 USD0SEC
    20,000 shares@ US$0.90Common StockSEC:0001415889-17-001015:0
    Canonical exit: 17 Sept 2017 (T+90)
  • ▲
    CHIEF EXECUTIVE OFFICERExecutivesH-Cyte, Inc.
    4,450 USD24SEC
    5,000 shares@ US$0.8919.5% of flowCommon StockSEC:0001415889-17-000937:0
    Canonical exit: 4 Sept 2017 (T+90)
  • ▲
    CHIEF EXECUTIVE OFFICERExecutivesH-Cyte, Inc.
    4,500 USD24SEC
    5,000 shares@ US$0.9019.7% of flowCommon StockSEC:0001415889-17-000937:1
    Canonical exit: 4 Sept 2017 (T+90)
  • ▲
    CHIEF EXECUTIVE OFFICERExecutivesH-Cyte, Inc.
    4,550 USD24SEC
    5,000 shares@ US$0.9120.0% of flowCommon StockSEC:0001415889-17-000937:2
    Canonical exit: 4 Sept 2017 (T+90)
  • ▲
    CHIEF EXECUTIVE OFFICERExecutivesH-Cyte, Inc.
    4,600 USD24SEC
    5,000 shares@ US$0.9220.2% of flowCommon StockSEC:0001415889-17-000937:3
    Canonical exit: 4 Sept 2017 (T+90)
  • ▲
    CHIEF EXECUTIVE OFFICERExecutivesH-Cyte, Inc.
    4,700 USD24SEC
    5,000 shares@ US$0.9420.6% of flowCommon StockSEC:0001415889-17-000937:4
    Canonical exit: 4 Sept 2017 (T+90)
  • ▲
    CHIEF EXECUTIVE OFFICERExecutivesH-Cyte, Inc.
    69,999 USD0SEC
    67,307 shares@ US$1.04Common StockSEC:0001415889-17-000267:0
    Canonical exit: 10 May 2017 (T+90)
  • ▲
    CHIEF EXECUTIVE OFFICERExecutivesH-Cyte, Inc.
    54,215 USD0SEC
    43,028 shares@ US$1.26Common StockSEC:0001415889-16-005891:0
    Canonical exit: 18 Jul 2016 (T+90)
  • ▲
    CHIEF EXECUTIVE OFFICERExecutivesH-Cyte, Inc.
    54,220 USD0SEC
    44,081 shares@ US$1.23Common StockSEC:0001415889-16-005612:0
    Canonical exit: 18 Jul 2016 (T+90)

9 of 9 declarations